Skip to main content
. 2007 Jun 1;24(6):618–625. doi: 10.1111/j.1464-5491.2007.02141.x

FIGURE 1.

FIGURE 1

Time courses for daily insulin dose, HbA1c and clinic FPG for people with Type 2 diabetes starting insulin while continuing rosiglitazone + metformin (□) or transferring to placebo (•). Data are mean ± se for ITT populations with LOCF, except for dose which is without LOCF. For statistical significance see Results and Table 2.